SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.
Three drugs that inhibit the immunoglobulin G (IgG) neonatal fragment crystallizable receptor (FcRn) were approved to treat generalized myasthenia gravis (MG) in recent years: efgartigimod (Vyvgart), ...
The aim of our study was to evaluate the efficacy of infliximab for the treatment of patients with refractory Kawasaki disease (KD) and investigate the dynamic changes of cytokines during infliximab ...
In 1996, a previously healthy 5-year-old girl presented to a local urgent care clinic with a 3-day history of fever and a progressive, generalized vesicular rash, diagnosed as varicella with a known ...
Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
1d
"I was fighting to survive": Patients still struggle with preauthorization despite promise of reform
Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.
A single intravenous ketamine infusion was safe and well-tolerated in older adults with mild cognitive impairment (MCI) and depression (MCI-D), with no serious adverse events (AEs) reported, a small ...
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG ...
MG Motor India finally revealed the new MG Majestor SUV in the Indian market. The SUV was first showcased at the 2025 Bharat Mobility Expo and is essentially a heavily updated version of the Gloster.
Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for the would-be blockbuster as a treatment for generalised myasthenia gravis (gMG). It isn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results